Advertisement

Search Results

Advertisement



Your search for all items matches 534 pages

Showing 301 - 350


colorectal cancer
issues in oncology

Citywide Effort Boosts New York City's Colorectal Cancer Screening Rates

A coalition formed by the New York City Department of Health and Mental Hygiene (DOHMH) to increase colorectal cancer screening rates in New York resulted in a 40% increase in screening rates over 4 years. The program may serve as a foundation for other communities to boost cancer screening rates,...

colorectal cancer
issues in oncology

10-Year Results of MOSAIC Trial Show Continued Survival Benefit of Adjuvant FOLFOX4 in Stage III Colon Cancer

Ten-year results of the MOSAIC trial, reported in the Journal of Clinical Oncology by André et al show a continued overall survival benefit with adjuvant FOLFOX4 (fluorouracil [5-FU] leucovorin plus oxaliplatin) vs 5-FU/leucovorin in patients with stage III colon cancer and in the entire...

colorectal cancer
issues in oncology

Disparities in Colorectal Cancer Death Rates Take a Large Economic Toll

Disparities in colorectal cancer death rates take a large toll on the national economy, with poorer, less-educated communities bearing the greatest burden, according to data presented at the Eighth American Association for Cancer Research (AACR) Conference on the Science of Cancer Health...

colorectal cancer

Pooled Analysis Indicates That Low but Not High BMI Is Associated With Poorer Outcome in Metastatic Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Renfro et al found that low but not high body mass index (BMI) was associated with poorer progression-free and overall survival in patients receiving first-line treatment for metastatic colorectal cancer. The analysis included individual...

colorectal cancer

Phase III Trials Fail to Show Noninferiority of Surgical Outcome for Laparoscopic vs Open Resection in Rectal Cancer

Two phase III trials, reported in JAMA by Fleshman et al and Stevenson et al, failed to show noninferiority of surgical outcome for laparoscopic vs open resection in patients with rectal cancer. ACOSOG Z6051 Trial In the American College of Surgeons Oncology Group (ACOSOG) Z6051 trial, reported...

colorectal cancer

No Reduction in Recurrent Colorectal Adenomas With Vitamin D and Calcium Supplementation

In a trial reported in The New England Journal of Medicine, Baron et al found that daily vitamin D and calcium supplementation did not reduce recurrence of colorectal adenomas in patients with recently diagnosed adenomas and no known polyps remaining after complete colonoscopy. Study Details In...

colorectal cancer
issues in oncology

Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People

Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the world's highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic. The...

colorectal cancer

Good Outcome With Neoadjuvant Chemoradiation and Local Excision in Clinical T2,N0 Distal Rectal Cancer

In a multi-institutional phase II trial (ACOSOG Z6041) reported in The Lancet Oncology, Garcia-Aguilar et al found that neoadjuvant chemoradiotherapy and local excision was associated with an acceptable disease-free survival rate, albeit not so high as anticipated, in patients with clinical stage...

colorectal cancer

Study Compares Maintenance Strategies After First-Line Oxaliplatin/Fluoropyrimidine/Bevacizumab in Patients With Metastatic Colorectal Cancer

In a German noninferiority phase III trial (AIO 0207) reported in The Lancet Oncology, Hegewisch-Becker et al found that maintenance treatment with bevacizumab (Avastin) was noninferior to a fluoropyrimidine plus bevacizumab in time to maintenance strategy failure following first-line treatment...

colorectal cancer
issues in oncology

Extended RAS Mutation Testing in Metastatic Colorectal Cancer to Predict Response to Anti-EGFR Antibody Therapy

As reported in the Journal of Clinical Oncology by Allegra et al, ASCO has issued a provisional clinical opinion (PCO) update on extended RAS mutation testing in metastatic colorectal cancer to predict response to anti-EGFR monoclonal antibody treatment. The update revises a 2009 PCO and is based...

breast cancer
colorectal cancer
lung cancer

A Tolerant Immune System May Increase Cancer Risk

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. “But we didn't...

colorectal cancer
issues in oncology

Many Patients Do Not Accurately Recall Important Colonoscopy Details as Time Lapses

As time lapses, many patients who have undergone a colonoscopy become less and less likely to recall when and where they last had the procedure performed, who the doctor was who performed it, whether polyps were found, and, if so, the number and size of those polyps, according to new study results...

colorectal cancer

All Relatives of Patients With Colorectal Cancer May Be at Increased Risk Regardless of Age at Diagnosis of Index Patient

All relatives of individuals with colorectal cancer are at increased risk for this cancer, regardless of the age of diagnosis of the index patient in the family, according to a study published by Samadder et al in Clinical Gastroenterology and Hepatology. These findings may impact future guidelines ...

colorectal cancer
issues in oncology

ECC 2015: Discovery of Differences Between Tumors of Younger and Older Patients With Colorectal Cancer May Lead to Better Treatments

Colorectal cancer is on the rise among younger patients. Although some of the younger-onset cases can be explained by hereditary factors, the majority arise spontaneously. Researchers have now found that tumors in younger patients with colorectal cancer may be molecularly distinct from those of...

colorectal cancer

Activity of Combined BRAF and MEK Inhibition in BRAF V600–Mutant Metastatic Colorectal Cancer

In a phase I/II study reported in the Journal of Clinical Oncology, Corcoran et al found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) produced responses in some patients with BRAF V600–mutant metastatic colorectal cancer. MAPK...

colorectal cancer

FDA Approves New Oral Medication for the Treatment of Refractory Metastatic Colorectal Cancer

The U.S. Food and Drug Administration today approved trifluridine/tipiracil (Lonsurf) for patients with metastatic colorectal cancer who have been previously treated with chemotherapy and biologic therapy and are no longer responding to treatment. The new agent is an oral combination of...

colorectal cancer
issues in oncology

Study Finds Racial Differences in BRAF/KRAS Mutation and Disease-Free Survival in Patients With Stage III Colon Cancer

In a study reported in the Journal of the National Cancer Institute, Yoon et al found that among patients with stage III colon cancer in the Alliance N0147 trial, Asians had the lowest rate of BRAF/KRAS mutations and longer disease-free survival vs whites among patients with N2 disease and that...

colorectal cancer
solid tumors

Synchronous vs Sequential Tumor Resection in Patients With Advanced Colorectal Cancer

About 20% of patients with colorectal cancer have cancers that have metastasized beyond the colon at the time of their diagnosis, with the liver being the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to...

colorectal cancer

Final Results of NO16968 Trial Show Improved Overall Survival With Adjuvant XELOX vs Bolus 5-FU/Leucovorin in Stage III Colon Cancer

As reported by Schmoll et al in the Journal of Clinical Oncology, the final results of the phase III NO16968 trial showed that adjuvant therapy with XELOX (capecitabine, oxaliplatin) improved overall survival vs fluorouracil (5-FU)/leucovorin in patients with resected stage III colon cancer....

colorectal cancer

Improved Overall Survival With FOLFOXIRI/Bevacizumab vs FOLFIRI/Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

In an updated analysis of the Italian phase III TRIBE trial reported in The Lancet Oncology, Cremolini et al found that FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) significantly prolonged overall survival in patients with unresectable metastatic...

colorectal cancer

Aspirin Reduces Obesity-Related Colorectal Cancer Risk in Patients With Lynch Syndrome

In an analysis of a randomized trial of aspirin in patients with Lynch syndrome reported in the Journal of Clinical Oncology, Movahedi et al found that obesity was associated with an increased risk of colorectal cancer, with the excess risk being restricted to those not receiving aspirin. ...

colorectal cancer
issues in oncology

Longer Colonoscopies Linked to Lower Rate of Colorectal Cancer

Research by a Veterans Affairs team has confirmed that longer-lasting colonoscopies are associated with lower cancer rates. Their findings were published by Shaukat et al in Gastroenterology, and were based on nearly 77,000 screening colonoscopies. Experts already know about the link between...

colorectal cancer

Long-Term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs May Be Associated With Reduced Colorectal Cancer Risk

A large population-based control study of the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs and colorectal cancer risk has found that taking 75 mg to 150 mg of aspirin for 5 years or longer was associated with a 27% reduced risk of colorectal cancer. In addition, 5 or more...

colorectal cancer
issues in oncology

Higher Coffee Intake Associated With Significantly Reduced Cancer Recurrence and Increased Survival in Patients With Late-Stage Colon Cancer

A large observational study investigating the effect of coffee consumption on advanced-stage colon cancer and survival has found that patients who drank four or more cups of coffee a day were 42% less likely to experience a recurrence than non-coffee drinkers and were 33% less likely to die from...

colorectal cancer

Adding Oxaliplatin to Preoperative Chemoradiotherapy and Postoperative Chemotherapy Improves Disease-Free Survival in Locally Advanced Rectal Cancer

Final results of the German phase III CAO/ARO/AIO-04 trial reported in The Lancet Oncology by Rödel et al showed that adding oxaliplatin to fluorouracil (5-FU)–based neoadjuvant chemoradiation and postoperative chemotherapy improved disease-free survival in patients with locally advanced ...

colorectal cancer
issues in oncology

Clinical Scoring System May Help Identify Appropriate Colorectal Cancer Screening Methods

Researchers investigating a risk index for colorectal cancer and advanced precancerous polyps among average-risk people have found that patients classified as low risk had fewer advanced adenomas than patients classified as high risk. Their findings suggest that those at low risk for colorectal...

issues in oncology
colorectal cancer

ERCC1 and Thymidylate Synthase Expression Identified as Promising Biomarkers in Metastatic Colon Cancer

Lower levels of ERCC1 (excision repair cross-complementation group 1) and thymidylate synthase expression may be predictive of longer survival in patients with metastatic colon cancer, according to a study by Choueiri et al in PLOS One. It was shown that patients with low levels of ERCC1 and...

colorectal cancer
issues in oncology

Genetic Test Predicts Colon Tumor Sensitivity to Radiation Therapy

Recent advances in the understanding of cancer have led to the development of more personalized therapies. Moffitt Cancer Center researchers have contributed to these advances by developing the first test that analyzes the sensitivity of tumors to radiation therapy. Their findings were published by ...

colorectal cancer
issues in oncology

Reemergence of Racial Disparity in Use of Adjuvant Chemotherapy in Stage III Colon Cancer

In an analysis reported in the Journal of Clinical Oncology, Murphy et al found that disparity in the use of adjuvant chemotherapy in white vs black patients with stage III colon cancer may have recently reemerged after a trend of increasing use in both racial groups.   Changes in Use Over...

colorectal cancer
issues in oncology

Study Finds One-Third of Colorectal Cancers Diagnosed Before Age 35 Are Hereditary

Although the prevalence of genetic risk factors, such as Lynch syndrome and familial adenomatous polyposis, has been studied in the general population of individuals with colorectal cancer, patients diagnosed as adolescents and young adults are not well represented in colorectal cancer studies. A...

colorectal cancer

Adding Neoadjuvant mFOLFOX6 After Chemoradiation May Improve Pathologic Complete Response Rate in Locally Advanced Rectal Cancer

In a phase II trial reported in The Lancet Oncology, Garcia-Aguilar et al found that adding neoadjuvant mFOLFOX6 (modified fluorouracil [5-FU], leucovorin, oxaliplatin) after chemoradiation improved the pathologic complete response rate in patients with locally advanced rectal cancer undergoing...

issues in oncology
colorectal cancer

Circulating DNA and Protein Biomarkers May Be Associated With Benefit of Regorafenib in Metastatic Colorectal Cancer

In a retrospective study reported in The Lancet Oncology, Tabernero et al used commercially available BEAMing technology to assess plasma tumor DNA and protein levels in a subgroup of patients from the CORRECT trial of regorafenib (Stivarga) in metastatic colorectal cancer and examined the...

colorectal cancer

High-Dose Chemoradiotherapy and Watchful Waiting May Be Alternative to Surgery in Some Patients With Distal Rectal Cancer

In a Danish prospective observational study reported in The Lancet Oncology, Appelt et al found that high-dose chemoradiotherapy and watchful waiting may be an alternative to abdominoperineal resection in some patients with distal rectal cancer. Study Details In the study, 55 patients with...

cns cancers
gynecologic cancers
colorectal cancer
leukemia
lymphoma
skin cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers

A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...

colorectal cancer
issues in oncology

Modeling Indicates Greater Benefit Without Greater Cost for Increased Colorectal Adenoma Detection Rate in Colonoscopy Screening

In a study reported in JAMA by Meester et al, microsimulation modeling of data from a U.S. community-based health-care system showed that colorectal cancer incidence and mortality were reduced with increased adenoma detection rate in colonoscopy screening, with no increase in total costs. Study...

colorectal cancer

Study Identifies Geographic Hot Spots With the Highest Colorectal Cancer Death Rates

Gains have been made in the overall reduction in the death rates of colorectal cancer in the United States. A new study by Siegel et al has identified three distinct geographic hot spots where colorectal cancer death rates remain elevated over other parts of the country. These hot spots were found...

palliative care
issues in oncology
colorectal cancer

ESMO World GI 2015: Studies Confirm Regorafenib Benefit in Pretreated Metastatic Colorectal Cancer

The phase IIIb CONSIGN trial has confirmed the benefit of regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer, researchers announced July 3 at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract...

colorectal cancer
solid tumors
pancreatic cancer
supportive care

ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy

The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....

palliative care
colorectal cancer

ESMO World GI 2015: Low Body Mass Index Associated With Poorer Survival in Metastatic Colorectal Cancer

Although being overweight with a high body mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well as previously expected after treatment for advanced cancer, according to a new study from Duke Medicine. The study, which was...

palliative care
colorectal cancer
head and neck cancer

Development of New Blood Vessels Not Essential to Growth of Lymph Node Metastases

While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital (MGH) Cancer Center may have...

issues in oncology
colorectal cancer
issues in oncology

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment

Metastatic colorectal cancer patients have improved survival rates when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapeutic agents before they begin treatment, researchers at University of California (UC) San Diego...

colorectal cancer
issues in oncology

Specific Mutations in KRAS Codon 12 Associated With Poorer Overall Survival in Patients With Colorectal Liver Metastases

In a single-institution study reported in JAMA Surgery, Margonis et al found that particular KRAS codon 12 mutations were associated with significantly poorer overall survival among patients with colorectal liver metastases. Study Details This retrospective study included data from 331 patients...

breast cancer
colorectal cancer
health-care policy
issues in oncology
issues in oncology
issues in oncology
cost of care

Colorectal Cancer Screening Increase May Reflect Affordable Care Act Provision

Screening for colorectal cancer increased in individuals with a lower socioeconomic status after 2008, perhaps reflecting the Affordable Care Act’s removal of financial barriers to screening, according to a new analysis. The study, by American Cancer Society investigators, was published by...

colorectal cancer

ASCO 2015: New Targeted Treatment IMMU-130 Shows Activity in Patients With Metastatic Colon Cancer

Although various drugs have improved outcomes for metastatic colon cancer patients, researchers continually strive to find new agents to improve treatment. Antibody-drug conjugates are a promising option, due to the fact that they can deliver chemotherapy directly into a targeted cell, destroy...

colorectal cancer
solid tumors
lung cancer

ASCO 2015: Entolimod May Be a Promising Treatment Option for Many Solid Tumors

A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute, shared results from the first clinical study of the anticancer effects of the novel agent entolimod on May 30 at the 2015 ASCO Annual Meeting in Chicago (Abstract 3063). Their findings confirm ...

colorectal cancer
issues in oncology

ASCO 2015: Colorectal Cancer Genetically Different in Older and Younger Patients

Although the overall rate of colorectal cancer is declining, colorectal cancer specifically among young patients is increasing. Previous studies have shown that colorectal cancer in patients younger than 50 years old tends to be more aggressive than in older patients. A University of Colorado (CU)...

colorectal cancer
solid tumors
gynecologic cancers

ASCO 2015: Mismatch Repair Deficiency Predicts Response to Pembrolizumab Among Patients With Colorectal and Other Cancers

A phase II study identified the first genomic marker—mismatch repair deficiency—to predict clinical benefit of immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab (Keytruda). Among 50 patients with colorectal cancer, 62% of the 25 patients with mismatch...

colorectal cancer
issues in oncology

Very Overweight Teens May Double Their Risk of Bowel Cancer in Middle Age

Being very overweight in your teens may double the risk of developing bowel cancer by the time you are middle-aged, suggested research published by Kantor et al in the journal Gut. A high level of an indicator of systemic inflammation—erythrocyte sedimentation rate—at this age is...

colorectal cancer

Regorafenib Improves Overall Survival in Asian Patients With Previously Treated Metastatic Colorectal Cancer

In the phase III CONCUR trial reported in The Lancet Oncology, Li et al found that the multikinase inhibitor regorafenib (Stivarga) improved overall survival vs placebo in Asian patients with previously treated metastatic colorectal cancer. Regorafenib has been approved by the U.S. Food and Drug...

colorectal cancer

First-in-Class Antibody Mixture Shows Clinical Activity Against Treatment-Resistant, Advanced Colorectal Cancer

Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR (epidermal growth factor receptor) therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options. Over the past decade, some ...

Advertisement

Advertisement



Advertisement